Patents by Inventor Byoung S. Kwon
Byoung S. Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951130Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: GrantFiled: March 1, 2021Date of Patent: April 9, 2024Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Publication number: 20240101678Abstract: Provided are CAR-T compositions that are directed to HLA-DR. Certain provided HLA-DR CAR compositions exhibit low affinity for a polymorphic region of HLA-DR of a subject. Various in vitro and in vivo methods and reagents related to HLA-DR CAR-T are also provided. Methods described herein can include, for example, characterization of HLA-DR binding, proliferation of T-cells, as well as prevention and/or therapeutic treatment of cancer using a HLA-DR CAR-T composition provided herein.Type: ApplicationFiled: June 12, 2023Publication date: March 28, 2024Applicants: EUTILEX CO., LTD., NATIONAL CANCER CENTERInventors: Byoung S. KWON, Chungyong HAN
-
Patent number: 11905334Abstract: It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.Type: GrantFiled: February 5, 2021Date of Patent: February 20, 2024Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
-
Publication number: 20240016837Abstract: The present invention relates to a novel T-cell receptor binding to MR1, and a use thereof. Unlike a conventional customized anticancer immune T cell therapeutic agent, which are limitedly used depending on cancer type and the expression of cancer antigens according to human leukocyte antigen (HLA) type, T cells in which a T-cell receptor is expressed can be applied to all types of cancer regardless of HLA type.Type: ApplicationFiled: June 3, 2021Publication date: January 18, 2024Inventors: Byoung S. Kwon, Yeong Cheol Kim, Kwanghee Kim, Sunhee Hwang, Jiwon Chung, Jungyun Lee
-
Patent number: 11859004Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.Type: GrantFiled: January 26, 2021Date of Patent: January 2, 2024Assignee: EUTILEX CO., LTD.Inventors: Byoung S. Kwon, Seoung-Joo Lee, Young Ho Kim, Ho-Sik Oh, Joong Won Lee
-
Publication number: 20230242607Abstract: An interleukin (IL)-2 protein including a sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18. A pharmaceutical composition including the interleukin-2 protein and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 7, 2021Publication date: August 3, 2023Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Seoung Hyun LEE, Sun Woo IM, Jin Kyung CHOI, Hyun Tae SON, Joong Won LEE, Hanna LEE, Sunhee HWANG
-
Publication number: 20230151113Abstract: Provided herein are CAR-T compositions that are directed to GPC3, including a chimeric receptor, and engineered immune cells to GPC3. The disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells, optionally in combination with expression of IL-18. GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.Type: ApplicationFiled: March 18, 2021Publication date: May 18, 2023Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Kwanghee KIM, Jiwon CHUNG, Young Gyoon CHANG, Bo-Rim YI, Jungyun LEE, Seunghyun LEE, Sun-Woo IM, Jinkyung CHOI, Hyuntae SON, Hye Mi LEE
-
Publication number: 20230146706Abstract: Provided are CAR-T compositions that are directed to GPC3, including chimeric receptors, and engineered immune cells to GPC3. The disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells. GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.Type: ApplicationFiled: March 18, 2021Publication date: May 11, 2023Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Kwanghee KIM, Jiwon CHUNG, Young Gyoon CHANG, Bo-Rim YI, Jungyun LEE, Seunghyun LEE, Sun-Woo IM, Jinkyung CHOI, Hyuntae SON, Hye Mi LEE
-
Publication number: 20220275083Abstract: The present invention provides a bispecific epitope binding protein comprising an anti-4-1BB agonist antibody and a PD-1 protein or a fragment thereof that binds to PD-L1 with high affinity. The bispecific epitope binding protein simultaneously and independently binds to 4-1BB and PD-L1, which engage 4-1BB upregulated T cells, especially effector CD8+ T cells, with tumor cells expressing PD-L1. These interactions induce strong activation of the cytotoxic activity of anti-tumor effector CD8+ T cells by both blocking PD-1/PD-L1-mediated inhibitory signaling and activating 4-1BB-mediated costimulatory signaling in mouse models. This bispecific epitope binding protein has a much stronger oncolytic effect compared to each component alone.Type: ApplicationFiled: January 11, 2022Publication date: September 1, 2022Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Hanna LEE, Jin Sung PARK, Seung Hee HAN, Hyun Tae SON, Sun Woo IM, Hyeok-Jun PARK, Eunhye YOO, Sung Min PARK, Yeonji OH
-
Publication number: 20220249565Abstract: Provided are CAR-T compositions that are directed to a CAR including (i) an extracellular domain comprising an antigen-binding domain; (ii) a transmembrane domain; and (iii) an intracellular domain comprising a costimulatory endodomain, wherein the costimulatory endodomain comprises an intracellular signaling domain from 4-1BB/CD137 and five additional amino acids. The disclosure also provides vectors, compositions, and methods of treatment using the antigen binding molecules and engineered immune cells comprising the CAR. The CAR compositions provided herein can be used for the treatment of certain cancers.Type: ApplicationFiled: June 26, 2020Publication date: August 11, 2022Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Kwanghee KIM, Jiwon CHUNG, Young Gyoon CHANG, Bo-Rim YI, Jungyun LEE, Sae Rom LEE, Hyuntae SON, Hye Mi LEE, Eun Hye YOO
-
Patent number: 11395836Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.Type: GrantFiled: December 16, 2019Date of Patent: July 26, 2022Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Young Ho Kim, Mun Ki Kim, Kwang Hee Kim, You Hyun Kang
-
Publication number: 20220073586Abstract: Provided are PD-1 polypeptide variants including an extracellular domain that binds specifically to PD-L1, and a transmembrane domain or a fragment thereof. The disclosure also provides PD-1 Fc fusion proteins including an immunoglobulin Fc region, and a PD-1 polypeptide variant.Type: ApplicationFiled: September 8, 2021Publication date: March 10, 2022Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Seunghyun LEE, Hanna LEE, Jin Sung PARK, Jin Kyung CHOI, Seung Hee HAN, Sun Woo IM, Hyun Tae SON
-
Publication number: 20220041750Abstract: A bispecific epitope binding protein having a multimer of four single-chain chimeric polypeptides of two single-chain chimeric heavy chains and two single-chain chimeric light chains. The bispecific epitope binding protein has a first antigen binding domain that binds specifically to HER2 and a second antigen binding domain that binds specifically to 4-1BB.Type: ApplicationFiled: August 9, 2021Publication date: February 10, 2022Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Hanna LEE, Yeonji OH, Jin Sung PARK
-
Publication number: 20220031742Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: ApplicationFiled: March 1, 2021Publication date: February 3, 2022Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Publication number: 20210401885Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.Type: ApplicationFiled: February 5, 2021Publication date: December 30, 2021Inventors: Byoung S. Kwon, Young Ho Kim, Mun Ki Kim, Kwang Hee Kim, You Hyun Kang
-
Publication number: 20210277139Abstract: Provided are IFN-?-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.Type: ApplicationFiled: February 5, 2021Publication date: September 9, 2021Inventors: Byoung S. Kwon, Seoung-Joo Lee, Joong Won Lee, Seunghyun Lee
-
Publication number: 20210261681Abstract: It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.Type: ApplicationFiled: February 5, 2021Publication date: August 26, 2021Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
-
Patent number: 11072646Abstract: The present invention relates to a novel epitope that converts T cell to type 1 helper T (TH1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH1 cell and a method for converting T cell to TH1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody.Type: GrantFiled: January 9, 2018Date of Patent: July 27, 2021Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Seung-Joo Lee
-
Publication number: 20210214455Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.Type: ApplicationFiled: January 26, 2021Publication date: July 15, 2021Inventors: Byoung S. Kwon, Seoung-Joo Lee, Young Ho Kim, Ho-Sik Oh, Joong Won Lee
-
Patent number: 11053298Abstract: The present invention relates to a novel epitope to convert T cell to type 2 helper T (TH2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (SEQ ID No.2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody.Type: GrantFiled: January 9, 2018Date of Patent: July 6, 2021Assignee: Eutilex Co., Ltd.Inventor: Byoung S. Kwon